COMMUNIQUÉS West-GlobeNewswire

Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
09/07/2018
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses Data support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to initiate around year- [...]
Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection
09/07/2018
Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences [...]
Quark Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
09/07/2018
Quark reached agreement with FDA on the overall Phase 3 trial design with a new innovative primary endpoint FREMONT, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc., a late clinical-stage [...]
Tauriga Sciences, Inc. Successfully Petitions OTC MARKETS GROUP to Expedite the Up-Lisitng of its Shares to the OTCQB Exchange
09/07/2018
NEW YORK, NY, July 09, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTC PINK: TAUG) (OTC PINK: TAUGD) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]
KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
09/07/2018
Results from Single Classroom-Style Trial Met Pre-Specified Primary and Secondary Endpoints Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 8:00 a.m. ET CORALVILLE, Iowa, July 09, [...]
Amryt Pharma plc: NHS England approves funding for Lojuxta
09/07/2018
9 July 2018 AIM: AMYT Amryt Pharma plc (“Amryt” or the “Company”) NHS England approves funding for Lojuxta Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that Lojuxta® ( [...]
FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata
09/07/2018
WAYNE, Pa., July 09, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated [...]
Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific
09/07/2018
HAIFA, Israel, July 09, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic [...]
Sunesis Pharmaceuticals Strengthens Senior Management Team
09/07/2018
SOUTH SAN FRANCISCO, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced three key new management appointments as part of the Company’s expansion of its development team [...]
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day
09/07/2018
SAN DIEGO and TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, [...]
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
09/07/2018
RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to [...]
Translate Bio Announces Closing of Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for Infectious Diseases
09/07/2018
LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia
09/07/2018
Primary Endpoint Cognition with Secondary Endpoints Parkinsonian Motor Symptoms and Sleep Function during 14-Week Study NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company [...]
Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
09/07/2018
Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference [...]
TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the 2018 Healthy Aging Summit
09/07/2018
Participation at two mid-July events will target healthcare practitioners IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to [...]
Athenex Names Timothy Cook as Senior Vice President of Global Commercial Oncology
09/07/2018
Mr. Cook was Previously VP and Chief Operating Officer of Oncology at Lilly BUFFALO, N.Y., July 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, [...]
Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc.
09/07/2018
RANCHO CUCAMONGA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). To date, [...]
Novo Nordisk A/S - Share repurchase programme
09/07/2018
Bagsværd, Denmark, 9 July 2018 - On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), [...]
New legal entity for LIDDS license partner in China
09/07/2018
LIDDS has agreed to transfer the licensing agreement for Liproca® Depot in China to Jiangxi Puheng Pharmaceuticals Ltd following a request from the owners of Jiangsu Ambition Medical. The change of legal entity will not [...]

Pages